Dublin, Dec. 17, 2024 (GLOBE NEWSWIRE) -- The "Myeloproliferative Disorders Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

The global market for Myeloproliferative Disorders Drugs was estimated at US$9.6 Billion in 2023 and is projected to reach US$12.9 Billion by 2030, growing at a CAGR of 4.3% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

The market for Myeloproliferative Disorders (MPD) drugs is expanding steadily due to the increasing incidence of these conditions, ongoing advancements in treatment options, and growing awareness among both patients and healthcare professionals. Current therapeutic options include cytoreductive therapies, JAK inhibitors, and supportive treatments like blood transfusions. With no known cure for MPD, the treatment landscape is evolving towards more targeted and effective management options.

What are the Current Trends in Myeloproliferative Disorders Drug Development?

The drug development landscape for MPD is shifting towards targeted therapies, which focus on inhibiting specific molecular pathways involved in disease progression. JAK inhibitors, such as ruxolitinib, have gained widespread acceptance as the first-line treatment for myelofibrosis and other MPD subtypes. Emerging trends in this space include the exploration of combination therapies that pair JAK inhibitors with other novel agents to enhance treatment efficacy and extend patient survival. Additionally, advances in molecular diagnostics are allowing for more precise identification of genetic mutations, such as JAK2, CALR, and MPL, which are commonly associated with MPD, thereby enabling personalized treatment strategies. The market is also witnessing an increased focus on developing therapies that target the bone marrow microenvironment, which plays a critical role in disease progression.

What Factors are Driving the Growth in the Myeloproliferative Disorders Drugs Market?

The growth in the Myeloproliferative Disorders drugs market is driven by several factors, including the increasing prevalence of these disorders, especially among aging populations, and advancements in molecular diagnostics that facilitate early detection and precise classification of MPD. The development of targeted therapies, such as JAK inhibitors, and ongoing research into new treatment combinations are enhancing the therapeutic landscape, offering patients more effective options. The rising focus on personalized medicine, supported by genetic testing, is also enabling more tailored and effective treatment strategies. Furthermore, the expansion of clinical trials and regulatory approvals for new drugs is providing patients with access to cutting-edge therapies, driving market growth.

Which Segments are Driving Market Growth?

By drug class, JAK inhibitors dominate the market due to their established role in managing myelofibrosis and polycythemia vera. The development of second-generation JAK inhibitors and novel agents targeting other pathways is expected to further expand this segment. Routes of administration include oral and injectable, with oral medications preferred for their ease of use and patient compliance. Hospital pharmacies and specialty pharmacies are the primary distribution channels, with the latter gaining prominence due to the specialized nature of MPD treatments. Geographically, North America holds the largest market share, driven by a higher prevalence of MPD, robust healthcare infrastructure, and early adoption of innovative therapies.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Ph+ Chronic myelogenous leukemia (CML) Drugs segment, which is expected to reach US$9.2 Billion by 2030 with a CAGR of a 3.7%. The Ph- Myeloproliferative Neoplasms (MPNs) Drugs segment is also set to grow at 5.7% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $2.6 Billion in 2023, and China, forecasted to grow at an impressive 6.5% CAGR to reach $2.7 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Key Questions Answered:

• How is the Global Myeloproliferative Disorders Drugs Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of major players in the Global Myeloproliferative Disorders Drugs Market such as AbbVie, Inc., Chia Tai Tianqing Pharmaceutical Group Company Limited, CTI BioPharma Corporation, Incyte Corporation, Italfarmaco S.p.A. and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 34 companies featured in this Global Myeloproliferative Disorders Drugs market report include:

• AbbVie, Inc.
• Chia Tai Tianqing Pharmaceutical Group Company Limited
• CTI BioPharma Corporation
• Incyte Corporation
• Italfarmaco S.p.A.
• Jubilant Therapeutics Inc.
• Kymera Therapeutics
• Merck & Co. Inc.
• PharmaEssentia
• Takeda Pharmaceutical Co. Ltd.

Key Attributes

Key Topics Covered

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

• Global Economic Update
• Myeloproliferative Disorders Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
• Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

• Rising Demand for Advanced Therapies for Blood Cancers Spurs Growth in Myeloproliferative Disorders Drugs Market
• Technological Advancements in Janus Kinase (JAK) Inhibitors Strengthen Business Case for Adoption
• Growing Focus on Personalized Medicine and Mutation-Targeted Therapies Expands Addressable Market
• Expansion of Myeloproliferative Disorders Drugs in Hematology-Oncology Practices Fuels Market Growth
• Increasing Adoption of Combination Treatment Regimens Expands Market Opportunities
• Technological Innovations in Epigenetic and Signal Transduction Inhibitors Propel Market Expansion
• Rising Focus on Prolonging Disease-Free Survival and Managing Symptoms Drives Demand for Myeloproliferative Disorder Drugs
• Growing Use of Myeloproliferative Disorder Drugs in Thrombosis Prevention and Symptom Control Expands Market Potential
• Rising Adoption of Novel Agents in Advanced and Refractory Disease Expands Addressable Market
• Technological Advancements in Cytokine Inhibitors and Molecularly Targeted Drugs Propel Market Growth
• Increasing Focus on Reducing Treatment Toxicity and Enhancing Compliance Drives Adoption
• Rising Demand for Myeloproliferative Disorder Drugs in Supportive and Palliative Care Strengthens Global Market
• Expansion of Myeloproliferative Disorder Drugs in Community-Based and Hospital-Based Oncology Settings Expands Market Opportunities

4. GLOBAL MARKET PERSPECTIVE

• Table 1: World Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
• Table 2: World Historic Review for Myeloproliferative Disorders Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
• Table 3: World 16-Year Perspective for Myeloproliferative Disorders Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
• Table 4: World Recent Past, Current & Future Analysis for Ph+ Chronic myelogenous leukemia (CML) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
• Table 5: World Historic Review for Ph+ Chronic myelogenous leukemia (CML) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
• Table 6: World 16-Year Perspective for Ph+ Chronic myelogenous leukemia (CML) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
• Table 7: World Recent Past, Current & Future Analysis for Ph- Myeloproliferative Neoplasms (MPNs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
• Table 8: World Historic Review for Ph- Myeloproliferative Neoplasms (MPNs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
• Table 9: World 16-Year Perspective for Ph- Myeloproliferative Neoplasms (MPNs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
• Table 10: World Myeloproliferative Disorders Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/fr4nvq

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Myeloproliferative Disorders Drugs Market

            CONTACT: ResearchAndMarkets.com 
Laura Wood,Senior Press Manager 
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470 
For U.S./ CAN Toll Free Call 1-800-526-8630 
For GMT Office Hours Call +353-1-416-8900